HIV Genetic Diversity and Drug Resistance

被引：48
作者：
Santos, Andre F. [1 ]
Soares, Marcelo A. [1 ,2 ]
机构：
[1] Univ Fed Rio de Janeiro, Lab Virol Humana, CCS, Ilha Fundao, BR-21949570 Rio De Janeiro, Brazil
[2] Inst Nacl Canc, Programa Genet, Rio De Janeiro, Brazil
来源：
VIRUSES-BASEL | 2010年 / 2卷 / 02期
关键词：
HIV-1; drug resistance; genetic diversity; subtypes; clinical response; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEASE INHIBITOR RESISTANCE; SINGLE-DOSE NEVIRAPINE; FULL-LENGTH GENOME; GROUP M SUBTYPES; NON-B SUBTYPES; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; TREATMENT-NAIVE; MOLECULAR CHARACTERIZATION;
D O I：
10.3390/v2020503
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Most of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological properties, including the response and susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are summarized in this review. Variations in drug susceptibility, in the emergence and selection of specific drug resistance mutations, in viral replicative capacity and in the dynamics of resistance acquisition under ARV selective pressure are discussed. Clinical responses to ARV therapy and associated confounding factors are also analyzed in the context of infections by distinct HIV genetic variants.
引用
收藏
页码：503 / 531
页数：29
相关论文
共 136 条
[1]   Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G [J].
Abecasis, AB ;
Deforche, K ;
Snoeck, J ;
Bacheler, LT ;
McKenna, P ;
Carvalho, AP ;
Gomes, P ;
Camacho, RJ ;
Vandamme, AM .
AIDS, 2005, 19 (16) :1799-1806
[2]  
Abecasis AB, 2006, ANTIVIR THER, V11, P581
[3]   Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients [J].
Agwale, SM ;
Zeh, C ;
Paxinos, E ;
Odama, L ;
Pienazek, D ;
Wambebe, C ;
Kalish, ML ;
Ziermann, R .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (01) :22-26
[4]  
Alexander CS, 2002, ANTIVIR THER, V7, P31
[5]  
[Anonymous], REP GLOB AIDS EP
[6]   HIV type 1 diversity in Northeastern Romania in 2000-2001 based on phylogenetic analysis of pol sequences from patients failing antiretroviral therapy [J].
Apetrei, C ;
Descamps, D ;
Collin, G ;
Robertson, DL ;
Pandrea, I ;
Groza, P ;
Prisecariu, L ;
Teodorescu, I ;
Luca, V ;
Brun-Vézinet, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (12) :1155-1161
[7]   Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (Subtype E) infection differ from subtype B infection [J].
Ariyoshi, K ;
Matsuda, M ;
Miura, H ;
Tateishi, S ;
Yamada, T ;
Sugiura, W .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) :336-342
[8]   Replicative Capacity Differences of Thymidine Analog Resistance Mutations in Subtype B and C Human Immunodeficiency Virus Type 1 [J].
Armstrong, Kimberly L. ;
Lee, Tun-Hou ;
Essex, M. .
JOURNAL OF VIROLOGY, 2009, 83 (09) :4051-4059
[9]   Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy [J].
Atlas, A ;
Granath, F ;
Lindström, A ;
Lidman, K ;
Lindbäck, S ;
Alaeus, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (03) :221-227
[10]   HIV-1 group N among HIV-1-seropositive individuals in Cameroon [J].
Ayouba, A ;
Souquières, S ;
Njinku, B ;
Martin, PMV ;
Müller-Trutwin, MC ;
Roques, P ;
Barré-Sinoussi, F ;
Mauclère, P ;
Simon, F ;
Nerrienet, E .
AIDS, 2000, 14 (16) :2623-2625
12345678910